The world's first enhanced embryo screening technology has been launched at Care Fertility, a private clinic specialising in infertility treatment.
Array CGH (comparative genomic hydridisation) can double the success of IVF by monitoring all 23 pairs of chromosomes, thereby improving on existing methods that only screen seven chromosomes and have been shown to have little value.
Dr Simon Fishel, founder of Care Fertility, said that the technology is a "real breakthrough" for the clinic and will help couples who are struggling to conceive.
"An earlier CGH trial in conjunction with a team in the USA doubled the number of embryos that implant from 25 to 50 per cent," he revealed.
"The new advanced Array CGH gives us great hope that egg or embryo screening will help increase the chances of conceiving."
Care Fertility is the only company to be given a license by the Human Fertilisation and Embryology Authority (HFEA) to use the Array CGH technology in the UK.